Indeed, VEGF stroke therapy can be considered to be a “double-edged sword”, inasmuch as acute treatment results in blood-brain barrier breakdown, whereas delayed treatment promotes neuroprotection and repair. The gene discussed is VEGFA; the disease is stroke disorder.